Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.68 |
| ▸ | RARG | P13631 | 9/20 | 0.68 |
| ▸ | RARA | P10276 | 9/20 | 0.68 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.50 |
| ▸ | HNF4A | P41235 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8660116 | 0.85 | RARB (0.56) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL8656889 | 0.85 | RARG (0.67) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL6379832 | 0.83 | RARG (0.64) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL31266609 | 0.81 | RARB (1.00) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL3453631 | 0.81 | RARB (1.00) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL7902107 | 0.80 | RARG (0.63) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL8656079 | 0.79 | RARG (0.58) | RARBRARGRARARXRAHNF4A | |
| SCHEMBL14425251 | 0.77 | RARB (0.63) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL5846597 | 0.76 | RARG (0.62) | RARBRARGRARARXRAACMSD | |
| SCHEMBL8442921 | 0.76 | RARG (0.55) | RARBRARGRARARXRAHNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255543-B1 | USE OF RETINOID-TYPE COMPOUNDS AS ANTIBACTERIAL AGENTS AGAINST STAPHYLOCOCCUS AUREUS | GALDERMA RES & DEV (FR) | 2010-09-01 | — | — | EP | claimed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | claimed |
| US-20030055110-A1 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-20 | — | — | US | claimed |
| EP-0658553-B1 | Polycyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | CIRD GALDERMA (FR) | 1998-11-04 | — | — | EP | claimed |
| US-5723499-A | Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | C.I.R.D. GALDERMA (FR) | 1998-03-03 | — | — | US | claimed |
| EP-0658553-A1 | Polycyclic aromatic compounds, pharmaceutical compositions containing them and uses thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-06-21 | — | — | EP | claimed |
| US-20260035353-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | SPECIAL PRODUCTS LINE S P A (IT) | 2026-02-05 | — | — | US | disclosed |
| US-20220281835-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | SPECIAL PRODUCTS LINE S P A (IT) | 2022-09-08 | — | — | US | disclosed |
| EP-3962887-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | Special Product's Line S.p.A. (IT) | 2022-03-09 | — | — | EP | disclosed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-0658553-B1 | Polycyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | CIRD GALDERMA (FR) | 1998-11-04 | — | — | EP | disclosed |
| US-5723499-A | Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | C.I.R.D. GALDERMA (FR) | 1998-03-03 | — | — | US | disclosed |
| EP-0658553-A1 | Polycyclic aromatic compounds, pharmaceutical compositions containing them and uses thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035353-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | TLR7, GANC, ARG1 | RARB 2413/4885RARG 2152/4885RARA 2620/4885 |
| US-20220281835-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | UROD, PPARD, PGLS | RARB 1666/4885RARG 2311/4885RARA 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.